Will MRK's Growing Pipeline Help Navigate the Looming Keytruda LOE?
Merck MRK has built a substantial portfolio of new products and pipeline candidates in areas like oncology, vaccines, neuroscience, and infectious disease.
Merck's phase III pipeline has almost tripled since 2021, supported by in-house pipeline progress as well as the addition of candidates through M&A deals. The company is now positioned to launch around 20 new vaccines and drugs over the next few years, with many having blockbuster potential.
Merck has several promising candidates in late-stage development, such as enlicitide decanoate/MK-0616, an oral PCSK9 inhibitor for hypercholesterolemia, tulisokibart, a TL1A inhibitor for ulcerative colitis, bomedemstat/MK-3543 for essential thrombocythemia, myelofibrosis and polycythemia vera and Daiichi-Sankyo-partnered antibody-drug conjugates (ADCs).
Merck and Daiichi Sankyo are co-developing three DXd ADCs — patritumab deruxtecan, ifinatamab deruxtecan and raludotatug deruxtecan for several types of cancer indications.
To foray into the lucrative obesity market, Merck has in-licensed global rights to an investigational oral GLP-1 receptor agonist, HS-10535, from China-based biotech Hansoh Pharma.
MRK's Keytruda Faces Patent Expiration in 2028
As Merck prepares for Keytruda's eventual loss of exclusivity in 2028, the company's expanding pipeline and new products are expected to play a key role in shaping its future business mix.
Besides working on various strategies to drive Keytruda's long-term growth, Merck is also pinning hopes on its new 21-valent pneumococcal conjugate vaccine, Capvaxive, and pulmonary arterial hypertension (PAH) drug, Winrevair, to boost its top line once Keytruda loses exclusivity. Both products have witnessed a strong launch so far.
Merck's long-acting monoclonal antibody, Enflonsia (clesrovimab), for the prevention of respiratory syncytial virus was approved by the FDA earlier this month.
Keytruda, a PD-L1 inhibitor approved for several types of cancer, generated sales of $7.21 billion in the first quarter of 2025, up 6% year over year. Our model estimates for Keytruda suggest a CAGR of 5.4% over the next three years.
However, at present, it is not quite clear whether Merck's new products and pipeline candidates can help the company successfully navigate the Keytruda LOE period and potential competition for the drug.
PD-L1 Inhibitors Competing With Keytruda
Keytruda faces competition from other PD-L1 inhibitors, including Bristol Myers ' BMY Opdivo, Roche 's RHHBY Tecentriq and AstraZeneca 's AZN Imfinzi.
BMY's Opdivo, like Keytruda, is approved across multiple cancer types, including lung, melanoma and kidney cancers. Bristol Myers recorded $2.26 billion in Opdivo sales during the first quarter of 2025, up 9% year over year.
Tecentriq is Roche's leading immuno-oncology drug approved for multiple cancer indications. RHHBY recorded CHF 870 million in Tecentriq sales in the first quarter of 2025.
AZN's Imfinzi generated sales of $1.26 billion in the first quarter of 2025, up 16%, driven by demand growth in lung and liver cancer indications. Imfinzi has strategically expanded its use across multiple cancer indications, strengthening AstraZeneca's oncology portfolio.
MRK's Price Performance, Valuation and Estimates
Year to date, shares of Merck have lost 19.9% compared with the industry 's decrease of 1.8%.
From a valuation standpoint, Merck appears attractive relative to the industry. Going by the price/earnings ratio, the company's shares currently trade at 8.56 forward earnings, lower than 14.92 for the industry and its 5-year mean of 12.85.
The Zacks Consensus Estimate for 2025 earnings has declined from $8.94 per share to $8.92, while the same for 2026 has decreased from $9.79 to $9.73 over the past 60 days.
Merck has a Zacks Rank #4 (Sell).
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AstraZeneca PLC (AZN): Free Stock Analysis Report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Bristol Myers Squibb Company (BMY): Free Stock Analysis Report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
33 minutes ago
- CTV News
Deep belly fat triggers inflammation. Here's how to reduce it
You can extend your health span by keeping visceral fat in check, doctors say.(ozgurcankaya/iStockphoto/Getty Images via CNN Newsource) Hiding deep inside the body, a dangerous type of fat wraps itself around vital organs such as the kidneys, liver and heart — triggering inflammation that can lead to insulin resistance and chronic diseases which cut life short. Called visceral fat, it can make bellies expand — but not for everyone. Even people who are thin can carry too much visceral fat around their organs, a phenomenon known as 'skinny fat.' 'Visceral fat is a marker for everything — insulin resistance, elevated cardiovascular risk, fatty liver and Type 2 diabetes — all very bad outcomes that limit a long and healthy life,' said Dr. Andrew Freeman, director of cardiovascular prevention and wellness at National Jewish Health in Denver. Excessive deep belly fat is even linked to long-term cognitive health, said preventive neurologist Dr. Kellyann Niotis, who researches Alzheimer's disease and Parkinson's disease risk reduction at the Institute for Neurodegenerative Diseases in Boca Raton, Florida. 'Visceral fat is metabolically unhealthy and secretes a lot of inflammatory chemicals that can cause brain atrophy and impact cognition,' Niotis told CNN in a prior interview. As the size of a person's belly grows, studies show the memory center of the brain shrinks and hallmark signs of Alzheimer's disease can appear — namely beta-amyloid plaques and tau tangles. This accelerated march toward dementia can begin as early as the 40s and 50s, well before any cognitive decline is apparent, according to researchers. How do you know if you have visceral fat? If visceral fat is about 10% of your body's total fat mass, that's normal and healthy, according to the Cleveland Clinic. So how do you know if that tummy starting to obscure your view of your feet is out of control? One way to tell is to measure your waistline. Non-pregnant women with a waist size greater than 35 inches (88.9 centimetres) and men with a waist greater than 40 inches (101.6 centimetres) are at higher risk from visceral fat, according to the U.S. Centers for Disease Control and Prevention. You can measure your waistline yourself: Without sucking in your tummy, wrap a tape measure over your waist at the top of your hip bone (typically across the belly button). Exhale normally and measure, making sure that the tape is parallel to the floor and snug, but not tight, across the skin. (No cheating by sucking in your stomach — this is your health at risk.) Another key sign is lean muscle mass. If you have more body fat than muscle mass, you're more likely to have visceral fat throughout the body, even the muscles, Freeman said. You can measure lean muscle mass with a yearly DEXA scan, a large noninvasive X-ray machine that measures bone density, internal visceral fat and muscle mass. There are also over-the-counter biometric scales that track percentages of body and visceral fat and lean muscle mass. Then there is common sense, Freeman said. Poor exercise and eating habits are a red flag for belly fat, now and in the future. 'Human beings were designed to be fit and strong and active,' he said. 'Eating ultraprocessed foods and not doing cardio and strength training are good signs that if you don't have excess now, you may soon — even if you don't look 'fat.'' Key ways to reduce visceral fat Want to make a change? Visceral fat is reversible with lifestyle changes, Freeman said. 'The real holy grail, the elixir of youth, the key to staying young and aging gracefully is to remain strong and fit,' he said. Always check with your doctor before beginning any new exercise program. Then start with cardio to get the heart pumping, Freeman said. A good method is to briskly walk for at least 30 minutes a day —'but when I say briskly, I mean fast enough to lose your breath and not be able to hold a conversation. Keep that up for a half hour at a minimum.' The critical next step is to add resistance, otherwise known as strength training, he added. 'When I tell people to go walking or biking or swimming or jogging, I usually recommend that they do resistance concurrently,' Freeman said. 'Carry some weights with them, or put on a weighted backpack, put resistance on the bike or bike uphill, and put fins on their hands when they swim so that there's resistance in the water. Do whatever they need to try to combine the cardio with strength training.' Some of the most effective resistance exercises for building lean muscle and losing fat require multiple joints in the body to work together, according to the nonprofit American Council on Exercise. Dead lifts, lunges, planks, presses, pull-ups and push-ups require many muscles that elevate oxygen use and the release of hormones such as adrenaline that increase blood flow to muscles and boost overall heart rate — both key goals. As you build lean muscle mass, try to add weight, increase sets and repetition, and reduce the breaks you take between exercises. If you're unsure how to do that without injuring yourself, seek out the advice of a physical trainer, the council suggests. 'If you're doing all the right things and you're not building muscle mass, talk to your doctor to rule out issues such as low testosterone that may be hindering your progress,' Dr. Richard Isaacson, director of research at the Institute for Neurodegenerative Diseases, told CNN previously. Address your diet Plant-based diets are excellent ways to improve nutrition and lose belly fat, experts say. 'Get rid of the standard American diet, filled with all the ultraprocessed foods and added fats, sugars and the like and switch to a predominantly whole foods diet,' Freeman said. The Mediterranean diet — which is more of a lifestyle than a diet — has won top honours since 2019 for its focus on eating fruits, vegetables, grains, olive oil, nuts and seeds, while emphasizing the importance of meals with family and friends and daily exercise. The diet also slashes consumption of sweets and recommends small amounts of dairy and meat, especially red meat. Fish, however, is a staple, especially fatty fish such as sardines. Older people who followed a lower-calorie Mediterranean diet and minimally exercised up to six days a week gained muscle and lost a significant amount of body fat by the end of a year and kept much of it off for three years, according to an October 2023 study. A May 2024 study found the Mediterranean dietary pattern cut the risk of death for women by about 25% for more than 25 years, with reductions in both cancer and cardiovascular mortality. Changing when you eat may also help. Try a pattern of eating called intermittent fasting or time-restricted eating, Freeman said. However, he added, it doesn't work for everyone. 'People who are struggling with weight loss have to get their bodies out of its routine, and that's very hard to do,' Freeman said. 'Some people, not everyone, respond by some degree to time-restricted eating. 'You eat breakfast at 11 o'clock, you eat dinner by five o'clock — so six hours a day you're eating, and 18 hours a day you're not. Combine that with strength and cardio training and change the type of fuel to whole foods. You put all those together, and magic things start to happen.' By Sandee LaMotte, CNN
Globe and Mail
an hour ago
- Globe and Mail
Dollar Tree Stock Is Soaring. Is This the Time to Buy?
Shares of Dollar Tree (NASDAQ: DLTR) are up more than 60% since mid-March and are fast approaching a 52-week high. As the company prepares to divest itself from its Family Dollar brand and embraces a new pricing model, Dollar Tree appears capable of thriving even as many retailers struggle with tariffs and economic uncertainty. There's a lot happening with Dollar Tree -- management changes, the Family Dollar mess, and its 3.0 pricing model. But all of it makes Dollar Tree a compelling stock that appears capable of producing oversized gains for investors. How is Dollar Tree threading the needle? And more importantly, is there still time for investors to join the rally? Family Dollar didn't work out Dollar Tree excels by providing low-cost household goods, food, cleaning supplies, and beauty products. Most items are priced at $1.25 (it used to be just a dollar, but the company began raising prices in late 2021 to offer a wider selection). Shares of Dollar Tree stock topped the $170 mark as recently as 2022, but began a long fall in 2024, stretching into the first quarter of 2025. Dollar Tree CEO Rick Dreiling stepped down, citing his health, and was replaced by Michael Creedon, who was formerly chief operating officer. Meanwhile, Family Dollar, which it purchased for $8.5 billion in 2015, continued to drag on the business. Dollar Tree finally shuttered several hundred Family Dollar stores in recent years, and then in 2024 announced it was exploring divesting itself of the brand. This March, Dollar Tree announced it had a buyer -- a partnership of hedge fund Brigade Capital Management and investment firm Macellum Capital Management, which are buying the stores for just over $1 billion. The deal is expected to close in this quarter. Not surprisingly, Dollar Tree stock started to recover soon after the announcement. Shares are up 61% since mid-March and 33% on a year-to-date basis. Dollar Tree stock has a long way to go from its 2022 ceiling, but it's only about 10% off its 52-week-high. Writing a new chapter The most interesting thing about Dollar Tree is its willingness to walk away from what made it famous. The company is embracing its 3.0 multi-price store format that includes wider store aisles, better signage, and a tiered price structure, where products range up to $7. Dollar Tree began switching stores over in 2024 and now has about 3,400 in the new format. Management hopes to have half of the company's stores working in the 3.0 format by the end of 2025. The format means that Dollar Tree can expand its offerings and draw in additional customers at higher price points. Same-store sales in the first quarter of fiscal 2025 (ending May 3) showed a 5.4% gain, which management attributed to higher prices and greater traffic. Gross profit increased to $1.6 billion, thanks to lower freight and occupancy costs. Adjusted earnings per share came in at $1.26. Dollar Tree opened 148 stores during the quarter and now has more than 9,000 locations, with plans to open a total of 400 stores this year. Management reiterated its full-year revenue guidance of $18.5 billion to $19.1 billion, while raising its guidance for earnings. The company is now expecting full-year EPS of $5.15 to $5.65, up from a range of $5 to $5.50. What's ahead for Dollar Tree? Even with higher-priced items, Dollar Tree is a discount retailer, and when people feel like their pocketbooks are getting squeezed, they are much more likely to look for consumer staples in a store that specializes in low prices rather than luxury items. So that helps Dollar Tree's outlook. But there's also the continued threat of tariffs, although President Donald Trump is developing the practice of announcing huge punitive tariffs as a negotiating ploy and then immediately rolling them back. Tariffs are a threat to any discount retailer, but perhaps even more to a store that sells many of its products for $1.25. If the tariffs come roaring back, Dollar Tree will need to make some changes either in pricing, the types of goods it offers, or will have to work some price relief with its suppliers. So is Dollar Tree a buy? Dollar Tree today is a pretty cheap stock -- the price-to-earnings ratio of 19.7 and the forward P/E of 18.3 are both attractive, as is its low price-to-sales ratio of 1.2 times. Now that the company is ridding itself of the Family Dollar fiasco and appealing to more consumers with its 3.0 multi-price format, Dollar Tree stock appears capable of setting a new 52-week high this summer. It's too early to say if it gets back to its 2022 heyday, but Dollar Tree is certainly on the right track. Should you invest $1,000 in Dollar Tree right now? Before you buy stock in Dollar Tree, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Dollar Tree wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor 's total average return is1,062% — a market-crushing outperformance compared to177%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 23, 2025
Globe and Mail
an hour ago
- Globe and Mail
3 Artificial Intelligence (AI) Stocks That Still Look Like Long-Term Winners
When you consider whether to invest in a company for the long term, you'll often find that stocks fall into two groups. The first includes stocks of companies that have done well. For those, it's about whether they can continue to perform at a high level. The other consists of flawed stocks, companies facing adversity or potential challenges that may deter investors. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Palantir Technologies (NASDAQ: PLTR), Apple (NASDAQ: AAPL), and Alphabet (NASDAQ: GOOG)(NASDAQ: GOOGL) are three well-known technology stocks representing a mix of both groups. Palantir has been one of the market's biggest winners in artificial intelligence (AI), while investors wonder whether Apple and Alphabet are losing their edge. Here is the skinny on each name and why all three can still be long-term winners. 1. This AI stock continues to defy gravity Palantir Technologies continues to chug higher, racking up a blistering 2,100% gain since 2023. The company has become a leader in developing AI software on its proprietary platforms for government and enterprise customers. And since launching AIP, its AI-focused platform, in mid-2023, Palantir's growth has continued to accelerate. The company still has fewer than 500 commercial customers in the United States, a tiny fraction of the country's 20,000 large corporations. Then, you factor in Palantir's close military ties (government contracts accounted for 55% of revenue in Q1 2025) at a time when America is involved in numerous geopolitical conflicts, and it's easy to envision years of high-speed growth. Despite its best efforts, Palantir's business hasn't kept pace with its share price. The stock has rocketed to a forward P/E ratio of 245, which is excessive, to say the least, for a business expected to compound earnings at an annualized rate of 31% over the long term. Given its growth momentum, both in the government and with commercial customers, Palantir's business appears poised to continue winning. That said, investors will probably want to wait for some significant dips to buy the stock at a more reasonable valuation. 2. Should investors worry about Apple's slow start in AI? AI seemed like a layup for Apple, with a wide-moat ecosystem spanning more than 2.35 billion active iOS devices worldwide. All Apple has needed to do is integrate AI capabilities into its iOS platform, and it would instantly be one of the leading consumer-facing AI companies, if not the leader. Yet Apple has struggled to launch notable AI features smoothly, and its underwhelming rollout of Apple Intelligence, its first attempt at AI, compelled the company to reorganize its AI team. The good news is that Apple's iOS remains one of the stickiest consumer ecosystems, which buys time for Apple to figure things out. People buy Apple products and use them for several years. The devices, whether it's a phone, computer, tablet, or watch, sync and work together. People become accustomed to iOS and develop a commitment to the ecosystem. Users may drift away from Apple eventually if it doesn't figure out AI, but it's unlikely that Apple's user base would implode overnight. Ultimately, Apple is a behemoth, a financial juggernaut with one of the world's most influential brands. While Apple may not deliver the same type of returns as in years past at a $3 trillion market cap, the stock should have a relatively high floor, based on the company's massive stock buybacks, growing dividend, and sticky business model. It's worth the leap of faith that Apple will solve its AI frustrations. 3. Is AI an opportunity or a threat to Google? Google's parent company, Alphabet, is facing some pressure from several directions. AI models have become popular enough to begin siphoning traffic away from traditional search engines, like Google. At the same time, U.S. regulators have successfully pursued litigation against Alphabet for anti-competitive practices, which could result in fines or even forced divestitures that would potentially impact its core advertising business. The adversity has one of the world's most prominent technology stocks trading at a P/E ratio of just 19 today. Yet, AI is arguably more an opportunity than a threat. Alphabet has integrated AI summaries into its search results, successfully monetizing them. Despite all the worries about AI, Google's ad revenue still grew by 10% in Q1 2025. Plus, Google Cloud is growing in size and profitability due to AI boosting demand for cloud services. If that weren't enough, Alphabet's autonomous ride-hailing business, Waymo, is continuing to expand its footprint across the United States and could eventually become a significant piece of Alphabet's business. When you put it all together, it seems that this technology giant will continue to remain a prominent force across the AI and technology space. That's an easy bet to make when the stock trades near its lowest valuation of the past decade. Should you invest $1,000 in Palantir Technologies right now? Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor 's total average return is1,062% — a market-crushing outperformance compared to177%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 23, 2025
